Peptide–Major Histocompatibility Complex class I presenting WT1, PRAME, and Survivin (pMHC-I (WT1/PRAME/Survivin))

Peptide–Major Histocompatibility Complex (pMHC) class I complexes are essential molecular assemblies that present intracellularly derived peptides on the cell surface for recognition by CD8+ T cells. In the context of oncology, tumor-associated antigens (TAAs) such as Wilms Tumor 1 (WT1), Preferentially Expressed Antigen in Melanoma (PRAME), and Survivin (BIRC5) are processed by the proteasome and loaded onto MHC-I molecules (typically HLA-A*02:01 in clinical applications). WT1 is a transcription factor overexpressed in various hematological and solid malignancies, while PRAME is a cancer-testis antigen and Survivin is an inhibitor of apoptosis protein (IAP) critical for tumor cell survival and proliferation. These pMHC complexes are highly attractive therapeutic targets because they allow the immune system to detect intracellular oncogenic proteins that are otherwise inaccessible to traditional antibody-based therapies. Current therapeutic modalities targeting these complexes include T-cell receptor-engineered T cells (TCR-T), TCR-mimic (TCRm) antibodies, and peptide vaccines designed to stimulate an endogenous cytotoxic T-lymphocyte response. By targeting these specific pMHC signatures, therapies can achieve high specificity for malignant cells while minimizing damage to healthy tissues that do not express these antigens in the context of MHC-I.

Other names

HLA-peptide complexesTumor-associated antigen pMHC complexesWT1-MHC complexPRAME-MHC complexSurvivin-MHC complexMHC-I restricted tumor antigens

T-cell receptor (TCR) binding and activation, T-cell mediated cytotoxicity, Antibody-dependent cellular cytotoxicity (ADCC) via TCR-mimic antibodies